載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.7822
−US$0.0098 · -1.24%
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
前收盤價
US$0.7822
−US$0.0098 · -1.24%
盤中時間採用ET。市場資料可能有所延遲。
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
日內區間
目前US$0.7822
52週區間
目前US$0.7822
盤中時間採用ET。市場資料可能有所延遲。
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
日內區間
目前US$0.7822
52週區間
目前US$0.7822
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 |
|---|---|---|---|
| 研究與開發 | 125.53萬 USD | 210.34萬 USD | 552.89萬 USD |
| 銷售、一般及管理費用 | 251.25萬 USD | 191.72萬 USD | 309.62萬 USD |
| 營業費用 | 377.24萬 USD | 402.68萬 USD | 863.67萬 USD |
| 利息收入 | 2.56萬 USD | 14.26萬 USD | 36.01萬 USD |
| 利息支出 | 10.09萬 USD | 5000 USD | 1萬 USD |
| 折舊和攤銷 | 12萬 USD | 11.86萬 USD | 12.1萬 USD |
| 營業利益 | −377.24萬 USD | −402.68萬 USD | −863.67萬 USD |
| 淨利 | −384.76萬 USD | −485.54萬 USD | −828.2萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年6月22日 | 1:10 | — | — |
已生效 2026年6月22日
1:10
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
